Search Results - "Becette, V"

Masses in mammography: What are the underlying anatomopathological lesions? by Berment, H, Becette, V, Mohallem, M, Ferreira, F, Chérel, P

“…Abstract The semiological description of masses in mammography is based on the BI-RADS system provided by the American College of Radiology. The contour is the…”
Get full text

Inter-laboratory quality control for hormone-dependent gene expression in human breast tumors using real-time reverse transcription-polymerase chain reaction by de Cremoux, P, Bieche, I, Tran-Perennou, C, Vignaud, S, Boudou, E, Asselain, B, Lidereau, R, Magdelénat, H, Becette, V, Sigal-Zafrani, B, Spyratos, F

“…Quantitative reverse transcription-polymerase chain reaction (RT-PCR) used to detect minor changes in specific mRNA concentrations may be associated with poor…”
Get full text

Overexpression of the stathmin gene in a subset of human breast cancer by BIECHE, I, LACHKAR, S, BECETTE, V, CIFUENTES-DIAZ, C, SOBEL, A, LIDEREAU, R, CURMI, P. A

“…Stathmin is a highly conserved cytosolic phosphoprotein that destabilizes microtubules. Stathmin, which has been proposed as a relay protein integrating…”
Get full text

Stellate images: anatomic and radiologic correlations by Cherel, P., Becette, V., Hagay, C.

“…The stellate images are the most well-known and most typical finding in the diagnosis of breast cancer. Its positive predictive value is very high. However, in…”
Get full text

Phase III trial (EORTC 10994/BIG 00-01) assessing the value of p53 using a functional assay to predict sensitivity to a taxane versus nontaxane primary chemotherapy in breast cancer: Final analysis by Bonnefoi, H. R., Bogaerts, J., Piccart, M., Mauriac, L., Fumoleau, P., Jassem, J., Becette, V., Cameron, D. A., Bergh, J., Iggo, R.

“…Abstract only LBA503 Background: Predictive markers of response to chemotherapy are lacking. Preclinical data suggest that p53 mutated tumors are resistant to…”
Get full text

Lung parenchymal changes secondary to cigarette smoking: pathologic-CT correlations by Remy-Jardin, M, Remy, J, Gosselin, B, Becette, V, Edme, J L

“…To determine the histopathologic basis for computed tomographic (CT) interpretation of smokers' lung and the accuracy of CT in the detection of alterations…”
Get more information

Use of radiology for the pathologist in the management of breast lesions by Guinebretière, J.M., Becette, V., Hagay, C., Belichard, C., Tardivon, A., Vanel, D.

“…Today radiology is an essential step in the pathological analysis of breast biopsies. It is determinant at each stage of the management of non palpable…”
Get full text

Unusual soft-tissue metastasis of an invasive lobular carcinoma mimicking fasciitis by EL KHOURY, M, CHEREL, P, BECETTE, V, DE MAULMONT, C, COSTES, V, TALMA, V, HAGAY, C

Get full text

Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma by BOUCHET, C, FERRERO-POÜS, M, HACENE, K, BECETTE, V, SPYRATOS, F

“…In a retrospective study of 488 women with primary breast cancer, after a median follow-up of 10 years, we sought interactions between disease-free survival…”
Get full text

Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions by MacGrogan, G, Arnould, L, De Mascarel, I, Vincent-Salomon, A, Penault-Llorca, F, Lacroix-Triki, M, Bibeau, F, Baranzelli, M C, Fridman, V, Antoine, M, Bécette, V, Brouste, V, Jacquemier, J, Mathoulin-Pélissier, S

“…Aims:  To assess the impact of cytokeratin (CK) 5/6 and E‐cadherin immunohistochemistry on diagnostic agreement of non‐invasive proliferative breast lesions…”
Get full text

A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer by Delorenzi, Mauro, Farmer, Pierre, Bonnefoi, Hervé, Anderle, Pascale, Cameron, David, Wirapati, Pratyakasha, Becette, Véronique, André, Sylvie, Piccart, Martine, Campone, Mario, Brain, Etienne, MacGrogan, Gaëtan, Petit, Thierry, Jassem, Jacek, Bibeau, Frédéric, Blot, Emmanuel, Bogaerts, Jan, Aguet, Michel, Bergh, Jonas, Iggo, Richard

“…Identifying factors that influence response to cancer chemotherapy is crucial for improving its efficacy. Mauro Delorenzi and his colleagues report that a…”
Get full text

821TiP GREAT: A multicentric cohort of advanced ovarian cancer (AOC) treated in real life with prospective collection of clinical data, tumor sample, and biomarkers (tBRCA, HRD) including genomic putative theranostic markers: A GINECO study by De La Motte Rouge, T., Berton, D., Kalbacher, E., Asselain, B., Collard, O., Rodrigues, M., Lefevre, L. Bengrine, Rouleau, E., Nogues, C., Just, P.A., Morel, A., Verriele, V., Boidot, R., Arnould, L., Buisson, A., Treilleux, I., Callens, C., Bataillon, G., Becette, V., Pujade-Lauraine, E.

Get full text

Identification of molecular apocrine breast tumours by microarray analysis by FARMER, Pierre, BONNEFOI, Herve, DUSS, Stephan, NICOULAZ, Anne-Laure, BRISKEN, Cathrin, FICHE, Maryse, DELORENZI, Mauro, IGGO, Richard, BECETTE, Veronique, TUBIANA-HULIN, Michele, FUMOLEAU, Pierre, LARSIMONT, Denis, MACGROGAN, Gaetan, BERGH, Jonas, CAMERON, David, GOLDSTEIN, Darlene

“…Previous microarray studies on breast cancer identified multiple tumour classes, of which the most prominent, named luminal and basal, differ in expression of…”
Get full text

Abstract P4-09-03: Prognostic and predictive value of COX2 in breast cancer, correlation with PIK3CA mutations by Tury, S, Becette, V, Assayag, F, Vacher, S, Marangoni, E, Bièche, I, Lerebours, F, Callens, C

“…Abstract Background: Cyclooxygenase-2 (COX2) is responsible for the synthesis of prostaglandins from arachidonic acid. This enzyme is weakly expressed in…”
Get full text

Abstract P4-01-03: Predictive value of FDG-PET/CT after neoadjuvant endocrine treatment in breast cancer by Boughdad, S, Champion, L, Becette, V, Cherel, P, Fourme, E, Edeline, V, Lemonnier, J, Lerebours, F, Alberini, JL

“…Abstract Background: Neaodjuvant endocrine therapy (NET) has demonstrated efficacy in terms of clinical response and outcome in hormone-receptor positive (HR+)…”
Get full text

Gene transcript assay by real-time RT-PCR in epithelial breast cancer cells selected by laser microdissection by BECETTE, V, VIGNAUD, S, REGNIER, C, LABROQUERE, M, FOURME, E, MENET, E, BIECHE, I, SPYRATOS, F

“…The cell type heterogeneity within clinical cancer tissue samples may affect the accuracy of gene expression analysis. In order to validate our laser…”
Get full text

Abstract P3-04-09: Genomic analysis to evaluate response to neoadjuvant anastrozole and fulvestrant in post-menopausal ER-positive HER2-negative breast cancer patients included in the UCBG CARMINA02 trial by Callens, C, Bessoltane, N, Ngo, C, Chemlali, W, Becette, V, Bernard, V, Delattre, O, Lemonnier, J, Mouret-Reynier, M-A, Andre, F, Bieche, I, Lerebours, F

“…Abstract Background: CARMINA02 is a non-comparative multicenter phase II randomized trial evaluating the clinical response rate after up to 6 months of…”
Get full text

Abstract P2-03-04: Lymphovascular invasion in breast carcinoma following neodjuvant chemotherapy is a strong prognosis factor by Hamy-Petit, A-S, Lam, G-T, Laas, E, Darrigues, L, Balezeau, T, Guerin, J, Livartowski, A, Sadacca, B, Pierga, J-Y, Vincent-Salomon, A, Bidard, F-C, Lerebours, F, Brain, E, Becette, V, Rouzier, R, Lae, M, Reyal, F

“…Abstract Purpose : Lymphovascular invasion (LVI) is a poor prognosis factor in breast cancer (BC), but data on its value in the neoadjuvant setting is scarce…”
Get full text

Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes by Bonnefoi, Hervé, MacGrogan, Gaetan, Poncet, Coralie, Iggo, Richard, Pommeret, Fanny, Grellety, Thomas, Larsimont, Denis, Bécette, Véronique, Kerdraon, Olivier, Bibeau, Frédéric, Ghnassia, Jean-Pierre, Picquenot, Jean-Michel, Thomas, Jeremy, Tille, Jean-Christophe, Slaets, Leen, Bodmer, Alexandre, Bergh, Jonas, Cameron, David

“…Background We explored, within the EORTC10994 study, the outcomes for patients with molecular apocrine (MA) breast cancer, and defined immunohistochemistry…”
Get full text

100 (PB-001) - 5-years relapse-free survival and predictive factors identification in HR-positive HER2-negative breast cancer patients treated with anastrozole or fulvestrant neoadjuvant endocrine therapy: Pooled analysis of the CARMINA02 and HORGEN phase II trials by Lerebours, F., Pulido, M., Fourme, E., Debled, M., Becette, V., Bonnefoi, H., Rivera, S., Mac Grogan, G., Mouret-Reynier, M.A., Tunon de Lara, C., Pierga, J.Y., Breton-Callu, C., Venat-Bouvet, L., Mathoulin-Pelissier, S., Kerbrat, P., Dalenc, F., Sigal, B., Bachelot, T., Lemonnier, J., Lerebours, Quenel-Tueux, N.

Get full text